Gail J. Roboz, MD - Maintaining “Intensity” for Better Outcomes in AML: Guidance on Modern, Intensive Upfront Platforms in Challenging Patient Populations
Go online to PeerView.com/BMM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Robust clinical evidence has proven that more effective upfront treatment platforms based on novel cytotoxics and targeted agents are now available for acute myeloid leukemia (AML)—including for difficult-to-treat subtypes (eg, secondary AML, mutation-defined disease). These new options have been shown to extend survival and, importantly, to allow more patients to reach hematopoietic stem cell transplant (HCT), a potentially curative treatment. Is a new ‘intensive’ treatment strategy forming in the context of modern AML care? Find out in this activity, based on a recent live symposium, and watch as an expert panel uses case-based conversations linked to the latest evidence on intensive upfront treatments to flesh out diagnostic strategies to capture challenging AML subtypes (including those with secondary AML or mutation-defined disease), determine the eligibility of patients for intensive therapeutic platforms, and select personalized upfront regimens with a goal of achieving robust remissions. Upon completion of this activity, participants should be better able to: Cite the diagnostic, prognostic, and therapeutic implications of baseline factors (eg, age, genetic/molecular features, functional status) for challenging AML subtypes—including secondary AML, mutation-defined disease, and higher-risk disease; Summarize current evidence on novel upfront induction/consolidation regimens for use in diverse AML settings; Recommend evidence-based, personalized upfront treatment platforms for patients with challenging AML subtypes, including those eligible for HCT; and Manage unique safety considerations associated with novel upfront treatment platforms, including innovative cytotoxic and targeted regimens